Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Multiple Sclerosis Journal - Experimental, Translational and Clinical|February 8, 2020
The diagnostic value of IgG index versus oligoclonal bands in cerebrospinal fluid of patients with multiple sclerosisCecilia Smith Simonsen, Heidi Øyen Flemmen, Trine Lauritzen, et al.
European Journal of Neurology|November 27, 2024
The influence of menopause on multiple sclerosisCecilia Smith Simonsen, Heidi Øyen Flemmen, Line Broch, et al.
Frontiers in Neurology|December 1, 2022
Rebaseline no evidence of disease activity (NEDA-3) as a predictor of long-term disease course in a Norwegian multiple sclerosis populationCecilia Smith Simonsen, Heidi Øyen Flemmen, Line Broch, et al.
Multiple Sclerosis and Related Disorders|June 26, 2022
Fatigue in multiple sclerosis is associated with socioeconomic factorsLine Broch, Heidi Øyen Flemmen, Cecilia Smith Simonsen, et al.
European Journal of Neurology|May 28, 2026
Differences in Income Growth Between People With Multiple Sclerosis and Controls: A Norwegian Cohort StudyAnne Høgset, Cecilia Smith Simonsen, Heidi Øyen Flemmen, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|April 2, 2021
High prevalence of fatigue in contemporary patients with multiple sclerosisLine Broch, Cecilia Smith Simonsen, Heidi Øyen Flemmen, et al.
Multiple Sclerosis and Related Disorders|September 14, 2023
"No association between disease modifying treatment and fatigue in multiple sclerosis"Line Broch, Heidi Øyen Flemmen, Cecilia Smith Simonsen, et al.
Multiple Sclerosis and Related Disorders|July 17, 2021
No significant differences in absenteeism or academic achievements in a Norwegian multiple sclerosis case control studyCecilia Smith Simonsen, Heidi Øyen Flemmen, Line Broch, et al.
Journal of Neurology|October 22, 2020
The course of multiple sclerosis rewritten: a Norwegian population-based study on disease demographics and progressionCecilia Smith Simonsen, Heidi Øyen Flemmen, Line Broch, et al.
Frontiers in Neurology|July 5, 2021
Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based RegistryCecilia Smith Simonsen, Heidi Øyen Flemmen, Line Broch, et al.
Pageof 3